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In Brief
Impaired activity of misfolded
formylglycine-generating enzyme (FGE)
results in multiple sulfatase deficiency
(MSD) in humans. Schlotawa et al. show
that recognition and quality control of
misfolded FGE by protein disulfide
isomerase (PDI) play a crucial role in the
manifestation of MSD as a severe
disease.
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Multiple sulfatase deficiency (MSD) is a fatal, in-
herited lysosomal storage disorder characterized
by reduced activities of all sulfatases in patients. Sul-
fatases require a unique post-translational modifica-
tion of an active-site cysteine to formylglycine that is
catalyzed by the formylglycine-generating enzyme
(FGE). FGE mutations that affect intracellular protein
stability determine residual enzyme activity and dis-
ease severity in MSD patients. Here, we show that
protein disulfide isomerase (PDI) plays a pivotal role
in the recognition and quality control ofMSD-causing
FGE variants. Overexpression of PDI reduces the re-
sidual activity of unstable FGE variants, whereas in-
hibition of PDI function rescues the residual activity
of sulfatases in MSD fibroblasts. Mass spectrometric
analysis of a PDI+FGE variant covalent complex al-
lowed determination of the molecular signature for
FGE recognition by PDI. Our findings highlight the
role of PDI as a disease modifier in MSD, which
may also be relevant for other ER-associated protein
folding pathologies.
INTRODUCTION
Multiple sulfatase deficiency (MSD) is a rare but fatal inherited
metabolic disorder in humans, characterized by deficient activ-
ities of all 17 sulfatases. Sulfatases are activated by post-trans-
lational modification of a conserved cysteine in their active site to
the catalytic Ca-formylglycine (FGly) residue in the endoplasmic
reticulum (ER) (Schmidt et al., 1995; Dierks et al., 1997). The
SUMF1 gene product formylglycine-generating enzyme (FGE)
catalyzes this unique modification, and SUMF1 mutations that
impair FGE function were identified as the molecular basis of
MSD (Dierks et al., 2003; Cosma et al., 2003). The manifestation
of severity in MSD has been attributed to residual functionality of
FGE (Schlotawa et al., 2008; 2011). Complete loss of FGE func-This is an open access article under the CC BY-Ntion is lethal, and it has been suggested that MSD-causing
SUMF1 mutations are hypomorphic, explaining the residual
functionality of FGE variants in sulfatase activation (Annunziata
et al., 2007). To date, about 40 different MSD-causing SUMF1
mutations have been reported, and the majority were missense
mutations that were predicted to affect the intracellular stability
of FGE (Dierks et al., 2005). FGE variants carrying such MSD-
causing missense mutations indeed showed clearly detectable
activity in vitro. In the cell, however, these variants were rapidly
degraded, which established that reduced intracellular stability
is the major determinant for severity in MSD manifestation
(Schlotawa et al., 2011, 2013). Thus, it is of high relevance to
understand the basic molecular aspects of misfolding in FGE
variants and the mode of recognition by the ER quality control
machinery, as holds true for numerous other ER-associated pro-
tein folding pathologies.
FGE is a soluble glycoprotein localized in the lumen of the ER.
It is also secreted and may even act as a paracrine enzyme (Pre-
usser-Kunze et al., 2005; Zito et al., 2007). The human protein
consists of a compact core domain and an N-terminal extension
that is proteolytically processed by furin during secretion (Enne-
mann et al., 2013). The core domain exhibits a novel fold with
very low secondary structure content, stabilized by two Ca2+
ions and two intra-molecular disulfide bridges (C218/C365 and
C235/C346) (Dierks et al., 2005). A pair of conserved redox-
active cysteine residues, C336 and C341, which are essential
for catalytic activity, line the catalytic site, arranged in a sur-
face-exposed groove of the core domain. FGE uses molecular
oxygen for cysteine oxidation, but the precise mechanism is un-
known. Structural and functional analyses predicted that FGE
could act as a cofactor-less monooxygenase (Dierks et al.,
2005; Roeser et al., 2006; Peng et al., 2015), whereas recent
data suggest a copper-dependent mechanism (Holder et al.,
2015; Knop et al., 2015). The function of FGE has been shown
to be a highly regulated process; retention in the ER is promoted
by interaction with protein disulfide isomerase (PDI) and ERp44,
whereas secretion is facilitated by interaction with ERGIC-53
(Fraldi et al., 2008; Mariappan et al., 2008b). Interestingly, inhibi-
tion of exit from the ER upon small interfering RNA (siRNA)-medi-
ated silencing of ERGIC-53 led to proteasomal degradation ofCell Reports 24, 27–37, July 3, 2018 ª 2018 The Author(s). 27
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Interaction of PDI with FGE Variants
(A) FGE-mediated activation of STS in MSDi cells. MSDi-TetOn cells were transiently transfected with the indicated combination of cDNAs. The amounts of FGE
and STS were monitored by western blotting (top). The measured specific activity of STS from cells coexpressing FGE variants were normalized to that of FGE-
WT (100%) and plotted in a bar diagram (bottom). The error bars represent mean ± SEM of values from three independent experiments.
(B) NEM-treated lysates fromHT1080 cells stably expressing FGEwere resolved in SDS-PAGE under non-reducing conditions andwestern blot-probedwith FGE
antiserum.
(C) Identification of PDI in complex with FGE-S155P. HT1080 cells stably expressing C-terminally His-tagged FGE-S155P were treated with NEM, and the lysate
was subjected to Ni-NTA chromatography. The elution fractions were resolved in SDS-PAGE under non-reducing conditions, and bands were visualized by
Coomassie staining. Excised bands were subjected to in-gel tryptic digestion. Tryptic peptides were analyzed by LC-MALDI mass spectrometry, and the data
were used for protein identification in the NCBInr database. The bands with identified monomeric FGE or FGE+PDI are indicated. Results were corroborated by
detailed analysis of purified FGE+PDI complex (Figure 3 and Fig. S3A).
(legend continued on next page)
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FGE, and it was suggested that PDI could function as a cofactor
for FGE (Fraldi et al., 2008).
In this study, we demonstrate that PDI plays an essential role in
the recognition and quality control of misfolded FGE. Impor-
tantly, we show that interfering with this function of PDI rescues
sulfatase activities in MSD patient fibroblasts. We were able to
purify an in vivo covalent complex between PDI and an FGE
variant and detect structural determinants underlying the forma-
tion of this complex. Our findings provide insight into the molec-
ular pathogenesis of MSD, which is probably also relevant for
other protein folding pathologies showing aggravation because
of stringent quality control.
RESULTS
PDI Specifically Interacts with Unstable MSD-Causing
FGE Variants
To assess the relation between in vivo residual activity and sta-
bility of FGE variants, we used a well-established steroid sulfa-
tase (STS) in vivo reporter assay in immortalized MSD (MSDi)
cells, a patient fibroblast cell line with very low endogenous
FGE levels (Mariappan et al., 2008a). We chose the stable FGE
variant A177P and unstable variants S155P, G247R, and
G263V, which cause late infantile mild and late infantile severe
forms of MSD, respectively (Schlotawa et al., 2008, 2011). Co-
expression of these variants with STS led to comparable
amounts of recombinant proteins (Figure 1A). The specific STS
activity measured for the different cells revealed that all FGE
variants tested showed residual functionality leading to STS
activities in the following order: A177P S S155P (75%–85%) >
G263V (40%) > G247R (20%) (Figure 1A, with wild-type [WT]-
FGE set to 100%). Surprisingly, S155P led to high STS activity,
comparable with that of A177P, although the S155P mutation
leads to a severe form of MSD in patients.
Cells stably expressing those FGE variants were treated
with N-ethylmaleimide (NEM) to block disulfide shuffling and
analyzed on western blots under non-reducing conditions.
Similar to FGE-WT, the FGE variants A177P, G247R, and
G263V showed homodimer formation (Figure 1B), mediated
through cysteines C50 and C52 (Preusser-Kunze et al., 2005).
In contrast, FGE-S155P showed a prominent band of
120 kDa (Figure 1B, FGE+X) that was also faintly visible for
the other FGE variants. Note that the amounts of monomeric
and dimeric forms of FGE-S155P are severely reduced
compared with all other variants, indicating that a substantial
amount of FGE-S155P is trapped in this complex. Under
reducing conditions, the FGE+X complex disappeared with a
concomitant increase in monomeric FGE, indicating a disul-
fide-mediated complex between FGE-S155P and an unknown
interacting protein (Figure S1A).(D) Co-immunoprecipitation of endogenous PDI along with endogenous FGE-S1
MSD patient cell line expressing FGE-S155P as endogenous protein were immun
and 50% of immunoprecipitation (IP) fractions were resolved in SDS-PAGE and
(E) Covalent and non-covalent interaction of FGE and PDI. FGE was immunopre
with either rabbit preimmune-serum (mock) or rabbit FGE-antiserum. 10% of the s
non-reducing conditions (top) or reducing conditions (bottom) and western blot-
(A–E) Representative single-gel analyses; vertical lines indicate lane cropping.To identify the interacting protein(s), we partially purified FGE-
S155P from NEM-treated HT1080 cells stably expressing His-
tagged FGE-S155P by Nickel-nitrilotriacetic (Ni-NTA) affinity
chromatography under strict non-reducing conditions. The Ni-
NTA eluate was resolved by SDS-PAGE. Coomassie-stained
bands were excised and analyzed by MALDI-TOF/TOF mass
spectrometry after tryptic digestion. Analysis of tryptic peptides
from the 120-kDa band identified both PDI (encoded by P4HB)
and FGE, whereas an 40-kDa band represented monomeric
FGE, as indicated in Figure 1C. Co-immunoprecipitation of
endogenous PDI as a complex with FGE-S155P ascertained
our mass spectrometry results (Figure S1B). To exclude the pos-
sibility that the observed interaction was an artifact of FGE over-
expression, we attempted to pull down PDI from untransfected
HT1080 or MSDi cells; the latter were derived from a homozy-
gous S155P patient. Analyzing anti-FGE immunoprecipitates
from these cells clearly showed a covalent interaction of PDI
with endogenous FGE-S155P (in MSDi cells) but not with endog-
enous FGE-WT(Figure 1D), which suggested a preference for
misfolded FGE. When we analyzed cells stably expressing
FGE-A177P, FGE-G247R, and FGE-G263V along with FGE-WT
and FGE-S155P controls, PDI was found to also exhibit covalent
interaction with other FGE variants, but less pronounced,
demonstrating a clear general preference for misfolded FGE
(Figure 1E). Of note, some weak interaction was also detectable
with FGE-WT but only under such overexpression conditions.
Moreover, weak monomeric PDI signals in the anti-FGE immu-
noprecipitates indicated significant non-covalent interaction in
all cases.
PDI Regulates Unstable and Stable FGE Variants
Differentially
Next we examined the functional consequence of interaction
between PDI and MSD-causing FGE variants. Using FGE-
S155P as an unstable model protein, we analyzed the effect of
PDI overexpression on FGE-mediated activation of sulfatases
in MSDi-TetOn cells (harboring FGE-S155P as the endogenous
variant). Co-transfection with a plasmid encoding STS and a
bidirectional promotor-driven plasmid encoding FGE plus myc-
tagged PDI allowed for expression of these three proteins under
the control of doxycycline (Figure 2A). Specific STS activities
measured were normalized to the very low activity resulting
from STS activation by endogenous FGE-S155P (Figure 2A,
lane 1). As expected, expression of FGE-WT led to a drastic
(91-fold) stimulation of STS activity (Figure 2A, lane 4) that was
slightly increased further (98-fold) in case of PDI co-expression
(Figure 2A, lane 5), in agreement with data published previously
(Fraldi et al., 2008). Remarkably, expression of FGE-S155P also
strongly (74-fold) stimulated STS (Figure 2A, lane 6), whereas, in
this case, PDI-coexpression largely abrogated this stimulating55P. Endogenous FGE from NEM-treated lysates of either HT1080 cells or an
oprecipitated using rabbit FGE antiserum. 10% of the starting material (Load)
western blot-probed with mouse monoclonal anti-PDI antibody.
cipitated from NEM-treated lysates from HT1080 cells stably expressing FGE,
tartingmaterial (Load) and 50% of the IP fractions (a-FGE) were resolved under
probed with mouse anti-PDI or anti-FGE.
Cell Reports 24, 27–37, July 3, 2018 29
A D
B E
FC
Figure 2. PDI Interferes with FGE-S155P Activity and Stability
(A) Coexpression of PDI impairs FGE-S155P-mediated activation of STS inMSDi cells. MSDi-TetOn cells were transiently transfectedwith pBI plasmids encoding
STS alone, myc-PDI alone, or myc-PDI plus FGE from a bidirectional promoter. STS activity assays were performed from cell lysates. STS-specific activities are
presented relative to STS alone-transfected cells (left). The asterisk indicates an unspecific signal.
(B and C) Coexpression of PDI only impairs the activity of unstable FGE variants. STS activity assays were performed in MSDi-TetOn cells coexpressing the
indicated proteins, and the amounts of STS, FGE, and myc-PDI were calculated from the western blot (B) (the asterisk indicates an unspecific signal). The
measured specific activities of STS from cells coexpressing FGE variants were normalized to that of FGE-WT(100%) and plotted in a bar diagram (C). The error
bars represent mean ± SEM of values from three independent experiments.
(D) Inhibition of PDI function by siRNA silencing in MSDi cells increases FGE-mediated STS activation for endogenous FGE-S155P and overexpressed FGE-
S155P but not for FGE-WT.
(E and F) Intracellular stability of FGE-S155P under siRNA-mediated silencing of PDI expression. HT1080 cells stably expressing FGE-WT or FGE-S155P treated
with PDI siRNA (si-PDI) or control siRNA (si-NC) were metabolically labeled with 35S-methionine/cysteine for 30 min and chased with unlabeled methionine/
cysteine for the indicated times. FGE was immunoprecipitated from the cell lysate, and medium and IP fractions were resolved in SDS-PAGE and analyzed by
autoradiography (E). The amount of FGE in the cells and medium was quantified and expressed as percentage of total FGE as a function of time (F).
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effect (byR90%), leaving a residual 5.6-fold increase in STS ac-
tivity (Figure 2A, lane 7). These data indicate that overexpressed
PDI effectively inhibited the residual sulfatase activation function
of FGE-S155P. Such an inhibitory effect, albeit only 2-fold, was
also observed for endogenous FGE-S155P in cells where PDI
alone was expressed along with STS (Figure 2A, compare lanes
1 and 3). When we extended this analysis to other MSD-causing
FGE variants, we observed a similar inhibitory role of PDI on the
residual activity of the unstable variants G247R and G263V,
whereas overexpression of PDI stimulated activity of the stable
FGE-A177P variant, leading to an increase (20%–25%) in STS
reporter activity to levels observed for FGE-WT co-expression
(compare Figures 2B and 2C with Figure 1A).
In a complementary approach, we found that reducing the
expression of endogenous PDI stimulated the FGE-S155Pmedi-
ated activation of STS (Figure 2D). Using siRNA-mediated PDI
silencing in MSDi cells, the residual STS activation by endoge-
nous as well as overexpressed FGE-S155P was increased, lead-
ing to 2.2- and 1.4-fold stimulation of the STS reporter sulfatase
compared with control-oligo (si-NC) treated cells (Figure 2D,
compare lane 4 with lane 3 and lane 8 with lane 7, respectively).
By contrast, FGE-WT-mediated activation of STS remained un-
affected by reduction of PDI expression levels (Figure 2D,
compare lane 6 with lane 5). Importantly, PDI knockdown in
MSDi cells also led to a 2-fold increase in endogenous sulfa-
tases, as tested for endogenous STS (Figure 2D, compare lane
2 with lane 1) and arylsulfatase A (ASA; Figure S2A) activities, re-
flecting the rescue of residual FGE-S155P functionality. To verify
whether such a rescue can also be achieved by interfering with
the in vivo interaction between PDI and FGE-S155P, we treated
MSDi cells with bacitracin, a membrane-permeable inhibitor of
PDI (Figure S2B). A 2- to 3-fold increase in the specific activity
of ASA was clearly measurable after 48 hr of treatment.
To verify whether its functional rescue is due to increased
intracellular stability of FGE-S155P, we analyzed the fate of
FGE-S155P (and FGE-WT as a control) upon PDI knockdown
by metabolic pulse-chase analysis (Figures 2E and 2F). Upon
overexpression, FGE-WT that escapes the ER retention mecha-
nism is secreted, and the secreted FGE is found in an N-termi-
nally truncated form (D72-FGE) because of furin-mediated pro-
cessing along the secretory pathway (Preusser-Kunze et al.,
2005; Ennemann et al., 2013). Interestingly, PDI silencing led to
an increase in the proportion of unprocessed FGE-WT in the
secreted fraction compared with untreated cells (Figure 2E,
top, compare lanes 7 and 14); however, the total amount of
FGE remained largely unchanged during the 3-hr chase (Fig-
ure 2F). In contrast, FGE-S155P was clearly absent in the secre-
tions, and only 30% of the intracellularly retained protein was
recovered after 2 hr of chase, indicating rapid degradation inFigure 3. Analysis of Tryptic Peptides from the Purified FGE-S155P+PD
FGE-S155P+PDI complex was purified fromMSDi cells stably expressing FGE S1
of cells with NEM. The purified complex was digested with trypsin in the presence
Tryptic peptides were analyzed by LC-MALDI mass spectrometry. In the fragmen
(center) and T90+T19 (bottom) were proved by the occurrence of mass signal qua
post-source decay, leaving peptide fragments that contain a cysteine (±0), thioald
Schnaible et al., 2002). Labeled are b- and y-ions, and precursor ion masses (m
cysteines and disulfide bridges or NEM modifications in the FGE-S155P+PDI co
32 Cell Reports 24, 27–37, July 3, 2018control cells (Figure 2E, compare lanes 1 and 4; Figure 2F).
PDI-silenced cells showed a delay in the degradation kinetics,
and 60% of the retained FGE protein was recovered after
2 hr (Figure 2E, compare lanes 8 and 11; Figure 2F). Increased
retention of other tested misfolded FGE mutants, but not
FGE-WT or FGE-A177P, also suggests that the intracellular sta-
bility of mutants G247R and G263V can be rescued by PDI
knockdown (Figure S2E). All the above data put together indicate
that PDI either positively (for stable FGE-WT and FGE-A177P) or
negatively (for unstable FGE-S155P, FGE-G247R, and FGE-
G263V) influences the residual activity of FGE.
The S155P Mutation Results in Non-Native Disulfide
Configuration in FGE, Leading to Covalent Interaction
with the PDI a’ Domain
To gain insight into the structural basis of interaction, we purified
the FGE-S155P+PDI complex from a stable cell line, co-ex-
pressing both proteins, to near homogeneity (Figure S3A). Cells
were pre-treated with NEM, and utmost care was taken to pre-
vent artificial disulfide formation and shuffling (STAR Methods).
The purified complex was subjected to in-solution tryptic diges-
tion, followed by LC-MALDI-TOF/TOF analysis of cysteine-con-
taining peptides (Figure 3). Except for the FGE C218-containing
peptide, for which the mass is beyond the upper detection limit,
we could detect all tryptic peptides of PDI and FGE with cyste-
ines either in disulfide-bridged, unmodified (free), or NEM-modi-
fied form.
In the FGE-S155P+PDI complex, C235 of FGE (in FGE-WT
bridged to C346) was found only reduced or modified with NEM
(Figure 3, top). In contrast, C346 formed a new disulfide bridge
to active-site C336 (Figure 3, center). In fact, C346 was exclu-
sively found within this new non-native disulfide bond, which
blocks the active-site C336 and is indicative of a loss of the native
stabilizing disulfide bridge betweenC235 and C346. C341 of FGE
(the native redox partner of C336 in the active site of FGE-WT)was
found forming an intermolecular disulfide bridge to C397 in the a’
domain of PDI, constituting the covalent interaction between PDI
and FGE-S155P (Figure 3, bottom). In the same peptide complex,
we could detect PDI C400modifiedwithNEM.ResidueC400 acts
as a resolving cysteine to release the substrate from PDI (Gilbert,
2011), which agrees with the presence of C400 as a free, NEM-
reactive thiol in the PDI/FGE complex, whereas C397 covalently
holds the misfolded FGE substrate. The cysteines C53 and C56
in the a domain of PDIwere not involved in intermolecular disulfide
formation with FGE-S155P. In fact, as verified by co-immunopre-
cipitation analysis, comparable amounts of PDI were pulled down
as a 120-kDa complex fromWT-PDI-, PDI-C53A-, and PDI-C53A/
C56A-expressing cells (Figure S3B, lanes 1-7). In contrast, a co-
valent complex or interaction per se of PDI with FGE-S155PI Complex by MALDI-TOF/TOF Mass Spectrometry
55P-His and His-PDI under strictly non-reducing conditions after pretreatment
of iodoacetamide to exclude an attack on disulfide bridges by free thiol groups.
t ion spectra, the presence of disulfide bridges in peptide complexes T27+T8
rtets (indicated by square brackets) generated by cleavage of the bridge during
ehyde (2), dehydroalanine (34), or dithiocysteine residue (+32) (according to
/z) are shown in brackets. The cartoons on the right indicate the positions of
mplex. Identified disulfide bridges and NEM modifications are shown in red.
AB
C
D
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was not detectable in either PDI-C397A- or PDI-C397A/C400A-
expressing cells (Figure S3B, lanes 8 to 11), suggesting that
mutating C397 of the a’ domain active site is sufficient to abolish
interaction with FGE-S155P, which further substantiates our
mass spectrometric data. Of note, mutating the key residues
F275 and I289 in a hydrophobic patch of the b’ domain of PDI
led to a reduction in covalent interaction, suggesting that recogni-
tion of exposed hydrophobic residues in FGE-S155P is a prereq-
uisite for covalent interaction (Figure S3C). In fact, earlier studies
had shown that PDI mediates hydrophobic interaction with its
substrates through this b’ hydrophobic patch (Pirneskoski et al.,
2004).
Covalent Interaction with PDI Is Determined by a Short
Peptide Structure Resulting from Non-native Disulfide
Bridging between Cysteines C336 and C346 in FGE
To understand the molecular basis of covalent interaction be-
tween misfolded FGE and PDI in further detail, we induced mis-
folding in FGE by mutating critical cysteines. Two disulfide
bridges between cysteine pairs C218-C365 and C235-C346 sta-
bilize the tertiary structure of FGE-WT (Dierks et al., 2005). As ex-
pected, all four C/A mutants showed high instability and,
different from FGE-WT, were not secreted, indicating destabili-
zation of the structure and failure to pass the intracellular quality
control (Figure S4A). Next we analyzed the interaction of these
mutants with PDI by co-immunoprecipitation (Figure 4A). We
were able to pull down monomeric PDI with FGE-C218A, FGE-
C346A, and FGE-C365A, indicating that these mutants inter-
acted non-covalently (Figure 4A, lanes 5, 9, and 11). Interest-
ingly, in cells expressing FGE-C235A, a large fraction of PDI
pulled down was found in an 120-kDa complex that also con-
tained FGE-C235A (Figure 4A, lanes 7 and 14). The data show
that disrupting the native disulfide configuration in FGE results
in covalent and non-covalent interactions with PDI. The forma-
tion of the covalent 120-kDa complex is exclusively dependent
on FGE-C346 that is not disulfide-bonded to its native partner
C235. Thus, the covalent intermolecular disulfide bridging of
PDI with both FGE-C235A and FGE-S155P (Figure 3, bottom) re-
lies on aberrant FGE intramolecular disulfide bridging involving
C346 (Figure 3, center), acting as a molecular determinant for
misfolding and PDI-mediated degradation induced by MSD-
causing missense mutations like S155P.
To gain insights into the role of C346 in determining the speci-
ficity for interaction with PDI, we resorted to in vitro analysis of co-Figure 4. The Non-native Disulfide Bridge between C336 and C346 Ge
(A) Co-immunoprecipitation of PDI and FGE structural cysteine variants. FGE wa
expressing FGE-WT or the indicated cysteine variants and His-tagged PDI with
starting material (Load) and 50% of the IP fractions (a-FGE) were resolved under
FGE, as indicated.
(B) Amino acid sequence of synthetic peptides derived from FGE-WT comprisin
serines replacing cysteines are indicated in red, and disulfide bridges between t
(C) Analysis of covalent interaction between the FGE-derived synthetic peptide
conditions by linear MALDI mass spectrometry. Peptide P2, simulating the non-n
mass shift of 1,802 Da in the linear MALDI spectrum, corresponding to the mass
(D) Bisphenol A inhibits the interaction between P2 and bovine PDI. Peptide P2
bisphenol A, and complex formation was analyzed by linear MALDI. Analysis wit
Note that linear MALDI analyses, as shown in (C) and (D), were performed on two d
a mass increase of 1,799–1,802 m/z, which matches the mass of P2. The averag
34 Cell Reports 24, 27–37, July 3, 2018valent interaction between purified recombinant PDI and peptides
derived from FGE encompassing cysteine residues C336, C341,
and C346, the cysteines involved in the abnormal disulfide
bridging leading to the formation of the FGE-S155P+PDI com-
plex. Three peptides with single cysteine mutations (P1, C346S;
P2, C341S; and P3, C336S; Figure 4B) were designed, with
each containing only two cysteines to result in a defined peptide
structure under oxidizing conditions; i.e., upon disulfide bridge
formation. The peptides were incubated with bovine PDI in a
redox buffer containing varying concentrations of reduced and
oxidized glutathione (GSH and GSSG) and, after blocking disul-
fide shuffling by NEM, analyzed by linear MALDI for complex for-
mation (Figure 4C). Peptide P2, containing C336 and C346,
mimicking the disulfide-bridging pattern in the FGE-S155P+PDI
heterodimer (Figure 3), efficiently formed a complex with PDI at
an oxidizing GSH/GSSG ratio of 1:3. Under the same conditions,
peptide P3 showed weak binding, whereas peptide P1, which
lacks C346, did not interact. The stability of the PDI+P2 complex
under MALDI conditions strongly suggests formation of a cova-
lent bond; i.e., an intermolecular disulfide bridge of PDI with
either C336 or C346 of P2. This interaction of P2 with PDI was
not observed either under completely oxidizing or completely
reducing conditions (Figure S4B), indicating a redox-dependent
function of PDI in intermolecular disulfide bond formation. The
data clearly show that the cyclic peptide structure stabilized by di-
sulfide bridging of C336 and C346 serves as amolecular determi-
nant for efficient interactionwith PDI. Interestingly, when the inter-
action between PDI and P2 was analyzed in the presence of
different concentrations of bisphenol A (BpA), a PDI inhibitor,
we observed a BpA dose-dependent decrease in the complex
between PDI and P2 (Figure 4D). It has since been shown that
BpA inhibits the isomerase activities of PDI by binding to the b’
domain (Hashimoto et al., 2012), it is conceivable that PDI, via
its isomerase function, acts to resolve the non-native disulfide
bridge between C336 and C346 in misfolded FGE.
DISCUSSION
The findings presented in this study show thatmisfolded FGE is a
physiological substrate of PDI and that PDI plays an essential
role in MSD by influencing both the stability and the residual ac-
tivity of MSD-causing FGE variants. Coexpression of PDI
severely reduced the residual activity of the unstable FGE vari-
ants S155P, G247R, and G263V. By contrast, the stable FGEnerates a Molecular Signature for Recognition by PDI
s immunoprecipitated from NEM-treated lysates from HT1080 cells transiently
either rabbit preimmune serum (mock) or rabbit FGE antiserum. 10% of the
non-reducing conditions and western blot-probed with mouse anti-His or anti-
g the active-site cysteines C336 and C341 as well as C346. The positions of
he two remaining cysteines are indicated.
s P1–P3 with bovine PDI in a redox buffer resembling physiological oxidizing
ative disulfide bridge found in FGE-S155P, is bound by PDI, as indicated by a
of peptide P2.
and bovine PDI were incubated in the presence of various concentrations of
h ethanol only served as a carrier control.
ifferent instruments. Formation of the P2-complex with PDI in both cases led to
e molecular mass calculated for reduced bovine PDI is 55,167 [M+H]+.
variant A177P, predicted to cause MSD because of compro-
mised sulfatase substrate binding (Dierks et al., 2005), was acti-
vated by PDI coexpression. We tested whether PDI might play a
direct role as a redox partner for FGE’s enzymatic activity. How-
ever, we did not observe a stimulating effect of PDI on FGE ac-
tivity in in vitro assays performed with purified proteins (Fig-
ure S2C). Rather, the data presented in this study agree with
the hypothesis that PDI acts as a folding catalyst improving
biogenesis of FGE-WT and stable variants, as demonstrated
by increasing their in vivo activity upon PDI co-expression. More-
over, for instable variants such as FGE-S155P, our data showing
that siRNA-mediated silencing of PDI expression led to a
decrease in the rate of degradation strongly suggest that the
drop in residual activity upon coexpression of PDI is, in fact,
due to accelerated degradation. Thus, PDI seems to act as a pro-
ductive folding catalyst for stable FGE but delivers its substrate
to the degradative pathway upon prolonged association with
FGE variants with folding problems. As a consequence, for
MSD patients, their apparent low FGE residual activity could
result, to a large extent, from PDI-mediated accelerated degra-
dation. In line with this, siRNA-mediated silencing of endoge-
nous PDI in the MSDi patient cell line (in which FGE-S155P is
the endogenous protein) led to a 2- to 3-fold increase in STS
and ASA sulfatase activities, indicating an increase in endoge-
nous FGE-S155P functionality. Considering that the majority of
the reported mutations in MSD have been predicted (and many
of them shown) to affect the intracellular stability of FGE, our
findings strongly suggest that PDI acts as a disease modifier in
most MSD patients. Thus, apart from the inherent debilitating ef-
fects of these destabilizing missense mutations affecting the ac-
tivity of FGE, the nature of misfolding and presentation of struc-
tural elements for efficient recognition by PDI determine MSD
severity.
What are those structural elements recognizedbyPDI?Wealso
found PDI in a covalent complex with FGE-WT, and coexpression
of PDI led to a low but significant increase in the activation of sul-
fatases, which is consistent with a previous study (Fraldi et al.,
2008). Physiologically, PDI obviously catalyzes correct formation
of the two stabilizing disulfide bridges (DSBs) in the FGE core
domain. It has been suggested that PDI-catalyzed DSB isomeri-
zation can occur, while the substrate is in a covalent complex
with PDI, by a series of intramolecular disulfide exchange reac-
tions in the substrate. Finally, release of PDI from the substrate
is triggered by the attack of a substrate cysteine on the intermo-
lecular DSB (Schwaller et al., 2003). Our data showing that only
the C235Amutation led to exclusive trapping of FGE in a covalent
complex with PDI suggested that the unavailability of C235 initi-
ates non-native DSB formation of its partner cysteine C346.
Most important, our mass spectrometry analysis of the purified
FGE-S155P+PDI complex demonstrated that an incorrect DSB
between C346 and the catalytic C336 leads to the exposure of
C341, another active-site cysteine that is identified by PDI and
forms a covalent intermolecular complex. Hence, by analogy
with the C235A mutant, it can be inferred that, as a consequence
of S155P mutation-induced misfolding, the intramolecular isom-
erization to resolve the incorrectly formed C336-C346 disulfide
in FGE is impaired because of unavailability of C235. In FGE-
WT this incorrect DSB could be resolved by C235 to form thenative C235-C346 DSB, and the resulting free C336 could act
as a resolving cysteine by attacking the intermolecular disulfide
between C341 of FGE and C397 of PDI, thereby releasing PDI.
However, the fate of FGE-S155P in complex with PDI is destined
for degradation, and it is possible that PDI-C400 could act as a
resolving cysteine to release PDI fromFGE-S155P. It has been re-
ported that the minimal construct of PDI required for performing
DSB isomerization reactions consists of the b’ and a’ domains
(Darby et al., 1998). Our data showing that the covalent interaction
of PDI with FGE is dependent only on the b’ and a’ domain thus
indicate that PDI mainly functions as a DSB isomerase to assist
FGE with proper folding. b’ is known to interact through a hydro-
phobic patch, as validated here by reduced FGE-S155P binding
to the PDI-F275W/I289A mutant. For the substrate side, our
finding that the 14-mer FGE peptide P2, exposing a tyrosine-
rich sequence uponC346-C336DSB formation, covalently bound
to PDI despite carrying a C341Smutation illustrates that this short
sequence determinant is sufficient for firm interaction. Covalent
binding of the peptide, however, did not occur under fully
oxidizing conditions (GSH:GSSG = 0:100), implicating that, in
the absence of C341, PDI has to resolve the artificial C346-
C336 DSB to undergo intermolecular DSB formation.
Our data showing that misfolded FGE variants in complex with
PDI are destined for degradation identify PDI as an important
component of ER-associated protein degradation (ERAD) of
misfolded FGE. PDI, through its oxidoreductase and/or chap-
erone function, is implicated in the ERAD of several misfolded
proteins by facilitating their unfolding for subsequent export
and degradation in the cytosol (Gillece et al., 1999; Molinari
et al., 2002; Lee et al., 2010). Our data suggest that PDI, after at-
tempts to catalyze proper folding, drives terminally misfolded
FGE to the degradative pathway. It is known that unfolding of di-
sulfide-containing glycoproteins requires reduction of existing
disulfides, and it is possible that PDI could reduce the disulfides
and unfold FGE. Interestingly, in a recent study, FGE was identi-
fied as an interacting protein with ERdj5 (Oka et al., 2013). ERdj5
is known to interact withmannosidases like EDEM1 and, through
its reductase function, has been shown to play an important role
in the ERAD pathway. Likewise, PDI has been shown to interact
with mannosidase Htm1p to initiate clearance of unfolded glyco-
proteins from the ER (Gauss et al., 2011). With regard to ERAD of
FGE, whether PDI works in co-operation with ERdj5 remains an
open question. With regard toMSD, which is an untreatable con-
dition so far, we propose that PDI acts as a disease modifier and
could serve as a target for therapeutic intervention.STAR+METHODS
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Antibodies
Rabbit polyclonal anti-FGE Preusser-Kunze et al., 2005 N/A
Rabbit polyclonal anti-STS Mariappan et al., 2008a N/A
Rabbit polyclonal anti-ASA Gieselmann et al., 1992 N/A
Mouse-monoclonal anti-PDI Abcam Cat. #ab2792; RRID: AB_303304
Rat-monoclonal anti-Hsc70 Abcam Cat. #ab19136; RRID:AB_444764
Mouse-monoclonal anti-RGS-His QIAGEN Cat. #34650; RRID:AB_2687898
Mouse-monoclonal anti-c-Myc Santa Cruz Biotechnology Cat. #sc-40; RRID:AB_627268
HRP conjugated goat anti-rabbit Invitrogen Cat. #31460; RRID:AB_228341
HRP conjugated goat anti-mouse Invitrogen Cat. #32430; RRID:AB_1185566
Chemicals, Peptides, and Recombinant Proteins
N-ethylmaleimide Thermo Fischer scientific Cat. #23030
Iodoacetamide Sigma Cat. #I1149
BisphenolA Sigma-Aldrich Cat. #239658
Bacitracin Sigma Cat. #B0125
Doxycycline ICNbiochemicals Inc. Cat. #195044
Protease inhibitor cocktail Sigma Cat. #P8340
Gluathione, reduced Sigma-Aldrich Cat. #G4251
Glutathione, oxidized Sigma Cat. #G4626
Trypsin Serva Cat. #37283
Protein disulfide isomerase Sigma Cat. #P3818
Insulin Sigma Cat. #I0516
FGE-peptide P1: CHRSYCYRYRSAAK This study N/A
FGE-peptide P2: CHRSYSYRYRCAAK This study N/A
FGE-peptide P3: SHRSYCYRYRCAAK This study N/A
Deposited Data
Proteomics This study PXD009758
Experimental Models: Cell Lines
HT1080 ATCC CCL-121
HT1080-TetOn Mariappan et al., 2008a N/A
MSDi Laboratory of Andrea
Ballabio, Italy
N/A
Oligonucleotides
For PCR-primer sequences, see Table S1 N/A N/A
siRNA targeting sequence: siPDI-1243: GGACCAUGAGAACAUCGUC This study N/A
siRNA targeting sequence: sicontrol-1243: GGACCAUCAGGCCACCUUC This study N/A
Recombinant DNA
pBI-FGE-HA Mariappan et al., 2008a N/A
pBI-STS Mariappan et al., 2008a N/A
pBI-FGE-A177P-HA This study N/A
pBI-FGE-S155P-HA This study N/A
pBI-FGE-G247R-HA This study N/A
pBI-FGE-G263V-HA This study N/A
pBI-FGE-C218A-HA This study N/A
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REAGENT or RESOURCE SOURCE IDENTIFIER
pBI-FGE-C235A-HA This study N/A
pBI-FGE-C346A-HA This study N/A
pBI-FGE-C365A-HA This study N/A
pBI-RGSHis-PDI This study N/A
pBI-Myc-PDI This study N/A
pBI-FGE-HA-Myc-PDI This study N/A
pBI-FGE-S155P-HA-Myc-PDI-C53A This study N/A
pBI-FGE-S155P-HA-Myc-PDI-C53AC56A This study N/A
pBI-FGE-S155P-HA-Myc-PDI-C397A This study N/A
pBI-FGE-S155P-HA-Myc-PDI-C397AC400A This study N/A
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PcDNA3.1-His-PDI This study N/A
Software and Algorithms
Compass for flexSeries 1.4 Part No 269833 Bruker Daltonics Bremen N/A
flexControl 3.4 (Build 135) Bruker Daltonics Bremen N/A
Warp-LC Version 1.3 (Build 136.138) Bruker Daltonics Bremen N/A
Proteinscape 3.1.5 474 (Build id: 20140711-1459) Bruker Daltonics Bremen N/A
biotools Version 3.2 (Build 6.32) Bruker Daltonics Bremen N/A
flexAnalysis Version 3.4 (Build76) Bruker Daltonics Bremen N/A
SequenceEditor Bruker Daltonics BioTools 3.2 SR4 Bruker Daltonics Bremen N/A
Bruker Compass HyStar 3.2-SR 2 (Build 44) Bruker Daltonics Bremen N/A
Hyphenation Star PP Version 3.2.44.0 Bruker Daltonics Bremen N/A
DisulfideDetect Version 1.0.2.2 Bruker Daltonics Bremen N/A
Other
Lipofectamine 2000 Thermo Fischer Scientific Cat. #11668027
Lipofectamine RNAiMAX Thermo Fischer Scientific Cat. #13778075
Pansorbin Calbiochem Cat. #507861CONTACT FOR REAGENT AND RESOURCE SHARING
Information and requests should be directed to and will be fulfilled by the Lead Contact, Thomas Dierks (thomas.dierks@
uni-bielefeld.de)
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines
Immortalized fibroblasts from anMSD patient (MSDi) (kindly gifted by Prof. Andrea Ballabio, Naples, Italy) and HT1080 cell lines were
maintained at 37C under 5% CO2 in Dulbecco’s modified Eagle’s medium (PAA) containing 10% fetal calf serum (PAN Biotech).
METHOD DETAILS
DNA constructs
The generation of pBI-FGE construct has been described earlier (Mariappan et al., 2008a). Briefly, the cDNA encoding human FGE
with a C-terminal HA tag is cloned into theMCSII of pBI vector (Clontech). FGE-cysteine variants were created by site-directedmuta-
genesis method using pBI-FGE as template and complimentary mutagenesis primers.Cell Reports 24, 27–37.e1–e4, July 3, 2018 e2
The PDIA1 cDNA was synthesized from total RNA, isolated from HeLa cells, by reverse transcription using the Omniscript RT
kit (QIAGEN) and an oligo(dT) primer. The first strand cDNA was amplified by PCR with primers PDIA1-NheF and PDIA1-ER5R
(Table S1). The PCR fragment was digested with NheI and EcoRV and cloned into MCS I of the pBI vector. Full-length sequencing
verified the correctness of the cDNA insert. A c-Myc tag or a RGS-6His tag was inserted after the signal peptide cleavage site
by sequential PCR-based reactions: PDIA1-NheF and PDI-mycR or PDI-RGS-6His-R were used for first amplification reaction;
PDI-mycF or PDI-RGS-6His-F and PDIA1-ER5R were used for the second. The resulting PCR products were used as templates
in an overlapping-extension PCR with primers PDIA1-NheF and PDIA1-ER5R to generate a product coding for myc-tagged or
RGS6His-tagged PDI. This product was digested with NheI and EcoRV for cloning into MCS I of pBI vector (for transient expression)
or into pcDNA3.1 for stable expression. For coexpression of myc/His-PDI with FGE or its mutants, myc/His-PDI cDNA was cloned
into the MCS I of pBI vector that already had wt-FGE or its mutants in the MCS II.
PDI mutants were created by site-directed mutagenesis using respective primers (the coding sequences of specific primers are
described in Table S1) using pBI-mycPDI as template. All PCR reactions were performed with Expand High fidelity PCR system
(Roche) and the resulting constructs were analyzed by full-length sequencing of coding regions to preclude any PCR-derived errors.
The coding sequences of specific primers are described in Table S1.
Cell culture and transfection
Transient transfections were performed with Lipofectamine 2000 as recommended by the manufacturer. 6 h post-transfection, pro-
tein expression was induced with medium containing 2 mg/ml doxycycline and 24 h post-induction, the cells and medium were
collected for further analysis. MSDi cells were transfected with pSB-FGE-His and pSB-FGES155P-His plasmids and grown in me-
dium containing 800mg/ml genticin (G418 sulfate, Invitrogen). For double expression, FGE cell lines were additionally transfected with
the pcDNA3.1HisPDI plasmid and grown in medium with 100 mg/ml hygromycin (Invitrogen). Stable clones were selected and tested
for PDI and/or FGE expression by SDS-PAGE and western blotting.
PDI RNAi experiments
The control (siControl-1243: 50-GGACCAUCAGGCCACCUUC) and PDI-specific siRNA (siPDI-1243: 50-GGACCAUGAGAACAUC
GUC-30) duplexes were purchased from IBA, Go¨ttingen (Germany). Transfection of siRNA duplexes were performed using Lipofect-
amine RNAiMax (Thermo Fischer) as recommended by the supplier. For MSDi-Tet-on cells, the siRNA duplexes were transfected at
50%–60% confluency and after 24 h, the cells were split and after 48 h of first transfection, the cells were transfected again with
siRNA duplexes and after 8 h, plasmid constructs were transiently transfected. 6 hr after transfection the cells were induced for pro-
tein expression with 2 mg/ml doxycycline. After 20 hr of induction, cells and medium were collected and analyzed. For the metabolic
labeling (pulse chase) experiments in HT180 cells stably expressing FGE-WT or –S155P, siRNA duplexes transfection was performed
as above and 24 h after second transfection, the pulse-chase analysis was performed.
Activity assay for sulfatases
Activity assays of steroid sulfatase (STS) and arylsulfatase A (ASA) were performed as described earlier (Conary et al., 1986).Western
blot signals were quantified using the AIDA 2.1 software package (Raytest). Signals of steroid sulfatase are given as relative amounts,
i.e., related to signal intensities detected in cells expressing steroid sulfatase only. Relative specific sulfatase activities were calcu-
lated, i.e., catalytic activity divided by the western blot signal (arbitrary units) and referred to that of cells expressing the sulfatase only
(relative specific sulfatase activity = 1).
Coimmunoprecipitation
Cells were washedwith PBS and incubatedwith PBS containing 20mMNEM (Sigma) for 5min at 37Cand harvested. The cell pellets
were resuspended in lysis buffer (PBS pH 7,4, 0.5%–1% (v/v) Triton X-100, 20 mM NEM, protease inhibitor cocktail (Sigma)) and
lysed by sonication. The cell lysate was centrifuged at 100,000 g for 30 min at 4C. Equal amounts of protein were incubated either
with rabbit preimmune serum or rabbit FGE anti-serum over night at 4C, followed by incubation with Pansorbin (Calbiochem) for 1 h
at 4C with end-over-end rotation. The Pansorbin pellet was processed according to a protocol described previously (Gieselmann
et al., 1992). The pellet was boiled in 1x Laemmli buffer without b-mercaptoethanol. 10% of the starting material prior to immunopre-
cipitation (load) and 50%–100%of the pellet fraction were subjected to SDS-PAGE either under nonreducing or reducing conditions,
transferred to a nitrocellulose membrane for western blotting.
Metabolic labeling and immunoprecipitation
HT1080 cells stably expressing FGE-WT-His or FGE-S155P-His and HT1080 cells transiently expressing FGE-WT or FGE-cysteine
variants were grown to near confluency in 3 cm plates. After starving for 1 h in medium depleted of methionine and cysteine, the cells
were pulsed with 35S-methionine/cysteine (Hartmann Analytic) for 30min. Cells andmedia were collected after incubation for various
time points in unlabeledmedium. Immunoprecipitation of FGE from cells andmediawas performedwith an FGE polyclonal antiserum
according to a protocol described earlier (Gieselmann et al., 1992). Pellets were solubilized in SDS-PAGE loading buffer and sub-
jected to SDS-PAGE and phosphorimaging (BAS 1000, Raytest). Densitometric quantification of FGE was done using the MacBAS
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FGES155P-His+HisPDI complex purification
For the purification of FGE-S155P-Hismonomer, FGE-S155P-His+His-PDI complex, andHis-PDI monomer,MSDi cell lines express-
ing these proteins were grown to 90%–100%confluence on cell culture dishes. Cells were incubatedwith 20mMNEM (Sigma) added
to the cell culture medium at 37C for 5 min prior to scraping off and lysis in lysis buffer (Tris- HCl 20mM, Triton X-100 0.1% (v/v),
Protease inhibitor- Mix 1% (v/v), NEM 20mM, pH 7.4). After clearing by centrifugation at 4C, the samples were loaded on a 1 mL
HiTrap column (GE Healthcare) using a A¨KTA Explorer 10S system (GE Healthcare) and washed with buffer I (Tris- HCl 20mM,
NaCl 500 mM, Imidazole 60 mM, NEM 20mM, pH 7.4) with a constant flow rate of 1 ml/min. Elution was performed running a 20
to 500 mM Imidazole gradient using elution buffer II (Tris- HCl 20mM, NaCl 500 mM, Imidazole 500 mM, NEM 20mM, pH 7.4) in
20 column volumes at the same flow rate. Selected elution fractions were acidified with TFA (0,1% (v/v)), loaded onto a Reverse
Phase C4 column (Jupiter C4, Phenomenex) and washed using buffer A (95% H2O, 5% acetonitrile, 0.1% TFA) on a SMART system
(GE Healthcare). Elution was performed with buffer B (5% H2O, 95% acetonitrile, 0.1% TFA), running a gradient from 0% to 70%
buffer B in 45 min with a flow rate of 100 ml/min. Part of the elution fractions were mixed with Laemmli buffer and analyzed by
SDS-PAGE and Coomassie staining under non-reducing conditions thereby monitoring the integrity of the protein complex. The
rest of the appropriate fractions were pooled from different identical runs, lyophilized and stored for further analysis.
Mass spectrometry
Purified and lyophilized protein samples (see above) were resuspended in 10 mM Tris-HCl, pH 8 containing 10 mM iodacedamide,
incubated for 25 min at 25C followed by a tryptic digest at 37Cwith 1 mg trypsin (Serva). The digestion was stopped by adding TFA
to a final concentration of 1% (v/v). Samples were separated, spotted and analyzed by LC-MALDI analysis (EASY-nLC, Proteineer fc
II spotter and Ultraflextreme MALDI-TOF/TOF mass spectrometer; Bruker Daltonics, Bremen) following a protocol described before
(Schulz et al., 2011). Data analysis was performed using the postprocessing software FlexAnalysis 3.3 (Bruker Daltonics).
Insulin-disulfide reduction assay for PDI
The enzymatic activity of PDI was assessed by a turbidimetric assay for reduction of insulin disulfide (Lundstro¨m and Holmgren,
1990). All reagents were freshly prepared on the day of experiment. 500 ml reactions containing 1 mg/ml (0.172 mM) insulin from
bovine pancreas (Sigma) in assay buffer (65 mM Sodium Phosphate, pH 7.0, 2 mM EDTA, 1 mM DTT) were incubated at 25C either
in the absence or presence of 15 mg of PDI (Sigma). Measurements for absorbance at 650 nmwere performed every 5min for 30 min.
Peptide binding assays
FGE-derived peptides P1, P2 and P3 were commercially synthesized (JPT Peptide Technologies GmbH, Germany). The sequences
are identical to the human FGE amino acid sequence from Cys336 to Arg349 with the exchange of the C-terminal arginine against
lysine for improved stability and one of three cysteines exchanged against serine in each peptide (see Figure 4B). The peptides were
dissolved in water, incubated in buffer containing 10 mM Tris HCl, pH 8 and 10 mM DTT for complete reduction of cysteines, and
acidified with 0.1% TFA. Peptides P2 and P3 were purified on a Luna C18 Reverse Phase HPLC column (Phenomenex) and P1
was purified using a Jupiter C4 Reverse Phase HPLC column (Phenomenex). Purity and redox state of every peptide were assessed
byMALDI-TOF/TOFmass spectrometry. Estimation of the amount of purified peptides in 50mMTris was done using a Cary 50 spec-
trophotometer (Varian) at 280 nm in 50 mM Tris HCl. For peptide binding assays, 20 pmol of purified bovine PDI (Sigma) dissolved in
20 mM Tris HCl, pH 8 were incubated with 400 pmol peptide at 37C in 100 mM Tris HCl, pH 8 containing 10 mM GSH: GSSG with
different ratios from 0:1 to 1:0 or after standardization at a ratio of 1:3 GSH: GSSG. The reaction was stopped after 20 min by adding
TFA to a final concentration of 1%. The effect of bisphenol A on PDI+P2 interaction was analyzed under the same conditions as
described above. The complexes between the peptides and bovine PDI were analyzed by Linear-modeMALDI TOFmass spectrom-
etry and the redox status of the peptides was analyzed by MALDI-TOF/TOF mass spectrometry in the reflectron mode, as described
before (Dimova et al., 2009) applying identical laser shots and distribution of shots on every spot following random walk mode. Sam-
ples with PDI or peptide alone served as controls.
QUANTIFICATION AND STATISTICAL ANALYSIS
Error bars are represented as mean ± SEM. Statistical analysis was performed with Microsoft Excel. Quantification methods and the
value of n is given in the figure legends and Method Details.
DATA AND SOFTWARE AVAILABILITY
The accession number for the mass spectrometry proteomics data reported in this paper is PRIDE: PXD00975.Cell Reports 24, 27–37.e1–e4, July 3, 2018 e4
